Compare FINW & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINW | MXCT |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.3M | 155.8M |
| IPO Year | 2021 | 2021 |
| Metric | FINW | MXCT |
|---|---|---|
| Price | $13.25 | $1.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $16.00 | $4.11 |
| AVG Volume (30 Days) | 40.9K | ★ 1.4M |
| Earning Date | 10-28-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.51 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | $39.89 | N/A |
| Revenue Next Year | $30.60 | $15.53 |
| P/E Ratio | $38.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.58 | $0.64 |
| 52 Week High | $19.86 | $1.81 |
| Indicator | FINW | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 72.20 | 57.00 |
| Support Level | $10.79 | $1.02 |
| Resistance Level | $14.62 | $1.54 |
| Average True Range (ATR) | 0.69 | 0.13 |
| MACD | 0.40 | 0.03 |
| Stochastic Oscillator | 86.05 | 48.67 |
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.